Research
Research

Spondyloarthritis: Why DMARDs May Not Be Enough for Every Patient

By Marcus Reid ·

The Gap Between Lab Values and Patient Experience

At the American College of Rheumatology annual meeting, researchers highlighted a persistent clinical puzzle. Many patients with spondyloarthritis continue to experience pain and functional limitations even when laboratory markers show inflammation has been controlled by disease-modifying anti-rheumatic drugs. This residual disease phenomenon challenges the assumption that suppressing inflammation automatically restores quality of life.

Clinicians often rely on C-reactive protein and other inflammatory markers to judge treatment success. However, patients frequently report ongoing back pain, stiffness, and reduced mobility despite normal lab results. This disconnect suggests that inflammation is only one component of the disease process. Non-inflammatory pain mechanisms, central sensitization, and psychosocial factors may sustain symptoms long after acute inflammation subsides.

What Does This Mean for Treatment Choices?

The finding pushes specialists to look beyond anti-inflammatory therapy. Physical rehabilitation, pain management strategies, and patient education may need to play a larger role in care plans. Some experts argue that treatment goals should shift from purely suppressing inflammation to restoring function and reducing pain perception.

Why do some SpA patients still hurt when labs look normal? Pain in spondyloarthritis can persist due to non-inflammatory mechanisms such as central sensitization or musculoskeletal deconditioning, even when CRP is within normal range.

Frequently Asked Questions

Do DMARDs fail to work in these cases? DMARDs effectively reduce inflammation, but they do not address all pain pathways. Residual symptoms often require a multimodal approach combining pharmacology with physical therapy and psychological support.

Should treatment targets change? Yes. Experts recommend redefining success to include patient-reported outcomes and functional improvement, not just biomarker normalization.